Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure

Crizotinib shows antitumor activity against C-ros oncogene 1-rearranged non-small-cell lung cancer (NSCLC). While corrected QT interval (QTc) prolongation and bradycardia are known as cardiac adverse effects, little is known about crizotinib-related heart failure. Our patient with C-ros oncogene 1-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Takahiko, Takahashi, Kosuke, Ota, Sachiko, Okumura, Nobumasa, Kondo, Haruka, Fukatsu, Asuki, Hara, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908384/
https://www.ncbi.nlm.nih.gov/pubmed/35732445
http://dx.doi.org/10.2169/internalmedicine.9157-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908384/
https://www.ncbi.nlm.nih.gov/pubmed/35732445
http://dx.doi.org/10.2169/internalmedicine.9157-21

Ejemplares similares